Since both the EPO/EpoR and the JAK2/STAT3 pathways have been implicated as molecular targets for ischemic stroke prevention and treatment, the activation of both of these cell pathways and their downstream signaling cascades is recognized as a promising therapeutic approach for stroke patients. This evidence concerns the gene JAK2 and stroke disorder.